Karyopharm Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

KPTI$0.04-27.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 29, 2024	KARYOPHARM THERAPEUTICS INC.
	By:	/s/ Richard Paulson
		Richard PaulsonPresident and Chief Executive Officer and Director(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

(Principal Financial and Accounting Officer)
Signature	Title	Date
/s/ Richard Paulson	President and Chief Executive Officer and Director	February 29, 2024
Richard Paulson	(Principal Executive Officer)
/s/ Michael Mason Michael Mason	Executive Vice President, Chief Financial Officer and Treasurer	February 29, 2024
/s/ Garen G. Bohlin	Director	February 29, 2024
Garen G. Bohlin
/s/ Barry E. Greene	Director	February 29, 2024
Barry E. Greene
/s/ Mansoor Raza Mirza	Director	February 29, 2024
Mansoor Raza Mirza, M.D.
/s/ Christy J. Oliger	Director	February 29, 2024
Christy J. Oliger
/s/ Deepika R. Pakianathan	Director	February 29, 2024
Deepika R. Pakianathan, Ph.D.
/s/ Chen Schor	Director	February 29, 2024
Chen Schor
/s/ Zhen Su	Director	February 29, 2024

Zhen Su, M.D.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.